Biohaven Ltd.

BHVN · NYSE · SIC 2834: Pharmaceutical Preparations
74
SEC Filings

Business Summary

Overview Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. We are advancing our innovative portfolio of therapeutics, leveraging our proven drug development experience and multiple proprietary drug development platforms. On October 3, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent) completed the distribution to holders o...

Next Earnings

Q2 FY2026 — expected 2026-08-16

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionBHVNdiscussed_in_filing Cybersecurity
topic_mentionBHVNdiscussed_in_filing Trusted Computing
topic_mentionBHVNdiscussed_in_filing Blockchain & Crypto
topic_mentionBHVNdiscussed_in_filing Regulation
topic_mentionBHVNdiscussed_in_filing Healthcare & Bio
topic_mentionBHVNdiscussed_in_filing Platform & Ecosystem
topic_mentionBHVNdiscussed_in_filing Sovereign & Government
topic_mentionBHVNdiscussed_in_filing Cybersecurity
topic_mentionBHVNdiscussed_in_filing Trusted Computing
topic_mentionBHVNdiscussed_in_filing Blockchain & Crypto
topic_mentionBHVNdiscussed_in_filing Regulation
topic_mentionBHVNdiscussed_in_filing Healthcare & Bio
topic_mentionBHVNdiscussed_in_filing Platform & Ecosystem
topic_mentionBHVNdiscussed_in_filing Sovereign & Government
topic_mentionBHVNdiscussed_in_filing Cybersecurity
topic_mentionBHVNdiscussed_in_filing Trusted Computing
topic_mentionBHVNdiscussed_in_filing Blockchain & Crypto
topic_mentionBHVNdiscussed_in_filing Regulation
topic_mentionBHVNdiscussed_in_filing Healthcare & Bio
topic_mentionBHVNdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-022025-12-310001935979-26-000020EDGAR103K words
2025-03-032024-12-310001935979-25-000015EDGAR
2024-02-292023-12-310001935979-24-000010EDGAR
2023-03-232022-12-310001935979-23-000009EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001935979-25-000092EDGAR35K words
2025-08-112025-06-300001935979-25-000068EDGAR
2025-05-122025-03-310001935979-25-000054EDGAR
2024-11-122024-09-300001935979-24-000085EDGAR
2024-08-092024-06-300001935979-24-000069EDGAR
2024-05-092024-03-310001935979-24-000046EDGAR
2023-11-142023-09-300001935979-23-000062EDGAR
2023-07-312023-06-300001935979-23-000052EDGAR
2023-05-122023-03-310001935979-23-000029EDGAR
2022-11-092022-09-300001935979-22-000011EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-020001935979-26-000022EDGAR7K words
2026-01-120001935979-26-000005EDGAR
2026-01-070001935979-26-000002EDGAR
2025-11-130001628280-25-052066EDGAR
2025-11-100001935979-25-000090EDGAR
2025-08-220001935979-25-000080EDGAR
2025-08-150001935979-25-000074EDGAR
2025-08-110001935979-25-000067EDGAR
2025-06-040001935979-25-000058EDGAR
2025-05-150001935979-25-000056EDGAR

74 total filings indexed. 50 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001935979
TickerBHVN
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedD8

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 03be96c1474609d957cf93a2b1766fd7f28a5c6a332046eb1ee303dc597e98be
parent: 958dcc9122ca0c66636bae63bb8465d2c8d560a5645e453c92147022e017ab2d
content hash: 1ebc334074960e75d3babc24d0e2157c4af2853e26ffb97c3e0c23f26f1343c1
signed: 2026-04-13T04:43:57.902Z
sources: 14 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf